Department of Pharmacology

3. Detection of Stress, Anxiety and Depression in IT/ ITES professionals in the Silicon Valley of India: A Preliminary study. SK Chaturvedi, S. Kalyanasundaram, A. Jagadish, Vikram Prabhu, Vikram Narasimha R. Primary Care & Community Psychiatry 2007, 12:2, 75 – 80.
4. Randomized, double blind, parallel group, comparative study of Deanxit (flupentixol and melitracen) versus dothiepin in the treatment of anxiety and/or depression co-morbid in general medical illness. HK Naidu, OP Singh, Jagadish A, Narasimha Vikram R. Medicine Update. Vol15.7.2007.
5. Research In Clinical Setting (RICS) of 5mg escitalopram (Cipralex) in the symptomatic treatment of mild to moderate anxiety and depressed patients in India. Narasimha Vikram R. Indian Journal of Clinical Practice. Vol18.7.2007.
6. Chronic low back pain, psychosomatic symptoms and the role of antidepressants. Narasimha Vikram R. Medicine Update. December 2007.
7. Safety and efficacy of escitalopram in post stroke depression. Rajesh B, Narasimha Vikram R, H.P. Pundarikaksha. Medicine Update. Vol15.No.9.2008.
8. A sub-analysis of efficacy and tolerability of Deanxit (flupentixol and melitracen) versus dothiepin in the treatment of anxiety and/or depression co-morbid in gastrointestinal disorders. Philip Augustine, Sanjay Jain, Narasimha Vikram R. Gastroenterology Today. 2008;12:27-32.

Papers In press

1. Efficacy and tolerability of Deanxit (flupentixol and melitracen) compared to dothiepin in the treatment of anxiety and/or depression co-morbid with neurological disorders, a sub-analysis.

Paper/ poster Presentation

1. “Open study of Clinical Efficacy and Tolerability of Citalopram in Indian patients with Major Depressive Disorder”; Charles Pinto, Vikram Narasimha, S. Nambi, SK Chaturvedi, Partha Choudhury, Shanthi Nambi, Malay Dave. Presented at 55th Annual National Conference of Indian Psychiatric Society (ANCIPS) 2003, Hyderabad. (Paper)
2. “A Comparative Assessment of the Clinical Efficacy and Tolerability of Citalopram and Fluoxetine in Indian patients with Major Depressive Disorder”; S. Nambi, Vikram Narasimha, SK Chaturvedi, Partha Choudhury, Shanthi Nambi. Presented at 55th Annual National Conference of Indian Psychiatric Society (ANCIPS) 2003, Hyderabad. (Paper)
3. Escitalopram: Efficacy and safety in major depression-results of a multicentric trial in India. Charles Pinto, Vikram Narasimha, J.K.Trivedi, G.K.Vankar, P.S.V.N.Sharma. Presented at 56th Annual National Conference of Indian Psychiatric Society (ANCIPS) 2004, Mysore. (Paper)
4. Cipralex (Escitalopram) Satisfaction Survey – Indian Data, Vikram Narasimha. Presented at the Evidence based seminar on mood disorders, December 5-6 2004, Kuala Lumpur Malaysia. (Poster)
5. Stress, anxiety and depression in IT/ ITES professionals in Bangalore. Presented at the Evidence based seminar on anxiety disorders, December 8-9 2006, Singapore. (Paper)

Clinical Drug Trials completed

1. A Comparative Assessment of the Clinical Efficacy and Tolerability of Citalopram and Fluoxetine in Indian Patients with Major Depressive Disorder. (phase III)
2. Open study of Clinical Efficacy and Tolerability of Citalopram in Indian patients with Major Depressive Disorder. (phase III)
3. “Screening study to identify early cognitive impairment in the elderly in Bangalore”, September 2002.
4. “Double blind randomized parallel group comparative study of Clinical Efficacy and Tolerability of an SSRI of innovator company& SSRI of company X in Indian patients with Major Depressive Disorder”, with Dr. G Prasada Rao, Hyderabad – February 2003. (Investigator Initiated Trial)
5. “A comparison of the safety and efficacy of branded original escitalopram vs generic escitalopram vs sertraline in major depression”, conducted by the Clinical Psychopharmacology Research Group, New Delhi – March 2004. (phase IV)
6. Research in clinical setting of escitalopram in the treatment of depressed patients in India.2006. (phase IV)
7. Randomized, double blind, parallel group, comparative study of Deanxit (flupentixol and melitracen) with dothiepin in the treatment of anxiety and depression comorbid in general medical illness. 2007. (phase IV)
8. Research in Clinical Setting (RICS) of escitalopram 5mg in the treatment of mild to moderate anxiety and depressed patients in India. 2007. (phase IV)
9. Research in Clinical Setting of escitalopram 10mg to assess for week-1 onset of action in the treatment of anxiety and depressed patients in India. 2007. (phase IV)

Ongoing Clinical Drug Trials

1. A survey of cutaneous adverse drug reactions

Future Plans

To establish Clinical Pharmacology Unit in the Hospital and to provide

1. Drug Information Services.
2. ADR Monitoring
3. Clinical Trials